Skip to main content
. 2021 Jun;9(11):924. doi: 10.21037/atm-21-1882

Figure 6.

Figure 6

Activation of NLRP3 eliminates the protective effect of UTI on MPP+ treated cells. (A) The NLRP3 activator Migericin significantly increased the protein expression of NLRP3, caspase-1, ASC, IL-1β, and IL-18, and eliminated the inhibited effect of UTI on NLRP3 pathway in MPP+ treated PC12 cells and SH-SY5Y cells. (B) Nigericin increased LDH release and eliminated the inhibited effect of UTI on LDH release in PC12 and SH-SY5Y cells. (C,D) Nigericin accelerated cell apoptosis eliminated the inhibited effect of UTI on apoptosis of PC12 and SH-SY5Y cells. (E) Nigericin significantly increased the levels of IL-1β, IL-6, and TNF-α, and eliminated the inhibited effect of UTI on inflammation of PC12 and SH-SY5Y cells. (F) Nigericin significantly increased DA levels and eliminated the promoting effect of UTI on DA of PC12 and SH-SY5Y cells. (G) Nigericin significantly increased TH protein expression and eliminated the promoting effect of UTI on TH protein of PC12 and SH-SY5Y cells. **, P<0.01 vs. Normal group; ##, P<0.01 vs. MPP+ group, &&, P<0.01 vs. MPP+ + UTI group. UTI, ulinastatin; LDH, lactate dehydrogenase; NLRP3, NOD-leucine rich repeat and pyrin containing protein 3.